The FDA’s Center for Drug Evaluation and Research issued warning letters dated 24 August 2026 to five online peptide sellers — TXP Innovations LLC dba Tex Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC and Peak Performance Peptides — posted 1 September 2026. Each followed a July 2026 review of the firm’s website and cited products including semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 as unapproved new drugs under section 505(a). FDA wrote that “research use only” labelling did not control, because website drug claims and the sale of bacteriostatic water as a reconstitution solvent established an intended use as injectable human drugs.
Sources: FDA warning letter to TXP Innovations LLC dba Tex Peptides, 24 August 2026 · FDA warning letter to Royal Peptides LLC, 24 August 2026 · FDA warning letter to NuScience Peptides LLC, 24 August 2026 · FDA warning letter to Peptide Partners LLC, 24 August 2026 · FDA warning letter to Peak Performance Peptides, 24 August 2026
